NasdaqGS:REGNBiotechs
Did Gene Therapy Milestones and Dupixent Expansion Just Shift Regeneron Pharmaceuticals' (REGN) Investment Narrative?
In April 2026, Regeneron Pharmaceuticals and partner Sanofi reported a series of milestones including FDA accelerated approval for Otarmeni, expanded U.S. pediatric approval for Dupixent in chronic spontaneous urticaria, and publication of positive Phase 3 cemdisiran data in generalized myasthenia gravis.
These developments underline Regeneron’s push into gene therapy, pediatric immunology, and complement-mediated diseases, broadening its portfolio beyond Eylea while keeping some programs,...